Adiponectin and Adiponectin Receptors in Human Pheochromocytoma

Isobe, Kazumasa; Fu, Ling; Tatsuno, Ichirou; Takahashi, Hideto; Nissato, Sumiko; Hara, Hisato; Yashiro, Tohru; Suzukawa, Kazumi; Takekoshi, Kazuhiro; Shimano, Hitoshi; Kawakami, Yasushi

doi:10.5551/jat.no885

Cited by 13 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This association is independent of menopausal status and family history of breast cancer. This is in accordance with the result of a case-control investigating pheochromocytoma[20]. Higher HMW adiponectin level is also negatively associated with breast cancer in postmenopausal, negative family history of breast cancer or BMI> = 24.0 subgroup.…”

Section: Discussionsupporting

confidence: 90%

“…More importantly, for cancers, HMW adiponectin were three times higher in patients with pheochromocytoma than in controls, yet lower HMW adiponectin was an independent risk factor for worse hepatocellular carcinoma histological grades and HMW adiponectin was decreased in patients with metastatic renal cancer compared with those with localized one. The role of HMW adiponectin in breast cancer is also being actively investigated [20,23,24]. For example, in a hospital-based case-control study of 74 female breast cancer patients and 76 controls, HMW was shown to be strongly and inversely associated with breast cancer risk, independent of classical risk factors such as leptin and the IGF-1 system[25].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating High-Molecular-Weight (HMW) Adiponectin Level Is Related with Breast Cancer Risk Better than Total Adiponectin: A Case-Control Study

et al. 2015

View full text Add to dashboard Cite

The level of total adiponectin, a mixture of different adiponectin forms, has been reported associated with breast cancer risk with inconsistent results. Whether the different forms play different roles in breast cancer risk prediction is unclear. To examine this, we measured total and high molecular weight (HMW) adiponectin in a case-control study (1167 sets). Higher circulating HMW adiponectin was negatively associated with breast cancer risk after adjusting for menopausal status and family history of breast cancer (P=0.024). We analyzed the relationship between adiponectin and breast cancer risk in 6 subgroups. Higher circulating HMW adiponectin was also negatively associated with breast cancer risk (P=0.020, 0.014, 0.035) in the subgroups of postmenopausal women, negative family history of breast cancer, BMI>=24.0. Total adiponectin was positively associated with breast cancer (P=0.028) in the subgroup of BMI<=24.0. Higher HMW/total adiponectin ratio was negatively associated with breast cancer (P=0.019) in the subgroup of postmenopausal women. Interestingly, in the subgroup of women with family history of breast cancer, higher circulating total and HMW adiponectin were positively associated with breast cancer risk (P=0.034, 0.0116). This study showed different forms of circulating adiponectin levels might play different roles in breast cancer risk. A higher circulating HMW adiponectin is associated with a decreased breast cancer risk, especially in postmenopausal, without family history of breast cancer or BMI>=24.0 subgroups, whereas higher circulating HMW adiponectin levels is a risk factor in women with a family history of breast cancer. Further investigation of different forms of adiponectin on breast cancer risk is needed.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Circulating High-Molecular-Weight (HMW) Adiponectin Level Is Related with Breast Cancer Risk Better than Total Adiponectin: A Case-Control Study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It is known that adiponectin has a favorable effect on insulin sensitivity and has anti-inflammatory and anti-atherosclerotic actions. Low adiponectin concentration is considered a risk factor of many complications of insulin resistance [18,20,50]. Dogruk Unal and co-authors showed that adiponectin level was significantly lower in SCS group of patients than those of the NFAI or control group [21].…”

Section: Discussionmentioning

confidence: 99%

Adipokine and cytokine levels in non-functioning adrenal incidentalomas (NFAI)

2018

View full text Add to dashboard Cite

Due to the fact that overweight or obesity is accompanied by hormonally active adrenal tumors: Cushing Syndrome-(CS) and Subclinical Cushing Syndrome (SCS), it is of high interest the correlation between different adipokines and cytokines secreted by adipose tissue, with metabolic disorders and hormonal activity in this group. Even in non-functioning adrenal incidentalomas (NFAI) elevated risk for cardiovascular disease and metabolic syndrome was demonstrated. The aim of the study was to investigate plasma adiponectin, leptin, resistin, tumor necrosis factor α (TNFα), interleukin 6 (IL6) and monocyte chemoattractant protein 1 (MCP1) levels in patients with NFAIs and healthy subjects. The study included 18 NFAI patients and 18 healthy subjects. The groups were homogeneous in terms of age, sex and body mass index (BMI). Patients with NFAI showed significantly higher circulating levels of pro-inflammatory cytokines compared to healthy controls (MCP 1: p < 0.001; TNFα p = 0.021; IL6 p = 0.012). On the other hand, adiponectin concentration was significantly lower in the NFAI group (p = 0.034). The serum leptin and resistin concentrations did not differ significantly between the two groups. Acquired results were not dependent on glucocorticoid and catecholamine secretion in NFAI patients. Also, there were no clear correlations between BMI and cytokine levels. It is possible that increased risk for cardiovascular and metabolic diseases reported in NFAI patients is at least partially dependent on adipose tissue activity.

show abstract

“…Although catecholamines are metabolic regulators of adipose tissue, their effects on adiponectin remain unclear. Furthermore, the adiponectin levels of patients with pheochromocytoma are controversial, with reports of their being increased ( 4 ), decreased ( 5 ), or unchanged ( 6 ). To date, there are no studies investigating the relationship between the adiponectin levels and visceral fat area (VFA) in pheochromocytoma patients.…”

Section: Introductionmentioning

confidence: 99%

Decreased Serum Adiponectin Level during Catecholamine Crisis in an Obese Patient with Pheochromocytoma

et al. 2018

View full text Add to dashboard Cite

We herein report the case of a 37-year-old man with both pheochromocytoma and visceral fat accumulation and describe the sequential changes in his adiponectin levels throughout the clinical course from catecholamine crisis until the follow-up for adrenalectomy. His adiponectin level decreased during catecholamine crisis and increased after adrenalectomy. However, his adiponectin level decreased again at two years postoperatively when his visceral fat area greatly increased. This case suggests that catecholamines and visceral fat volume may affect adiponectin metabolism in subjects with pheochromocytoma, which may precipitate cardiovascular complications in this endocrine disease.

show abstract

Adiponectin and Adiponectin Receptors in Human Pheochromocytoma

Cited by 13 publications

References 18 publications

Circulating High-Molecular-Weight (HMW) Adiponectin Level Is Related with Breast Cancer Risk Better than Total Adiponectin: A Case-Control Study

Circulating High-Molecular-Weight (HMW) Adiponectin Level Is Related with Breast Cancer Risk Better than Total Adiponectin: A Case-Control Study

Adipokine and cytokine levels in non-functioning adrenal incidentalomas (NFAI)

Decreased Serum Adiponectin Level during Catecholamine Crisis in an Obese Patient with Pheochromocytoma

Contact Info

Product

Resources

About